ESR1 and breast carcinoma: With the improvements to next-generation sequencing (NGS) technology, genomic analysis of blood samples from cancer patients has been conducted in various studies [6], and the detection of ESR1 mutations in circulating tumour DNA (ctDNA) in patients with breast cancer has been reported [7,8,9,10,11].